Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an announcement.
Australian Clinical Labs Ltd announced an update on its ongoing share buy-back program, revealing that a total of 1,006,789 securities had been bought back before the previous day, with an additional 196,687 securities purchased on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, providing pathology services. The company focuses on delivering diagnostic services to healthcare professionals and patients across Australia.
Average Trading Volume: 932,703
Technical Sentiment Signal: Sell
Current Market Cap: A$548.1M
Find detailed analytics on ACL stock on TipRanks’ Stock Analysis page.